Testing was not performed or missing for the presence of FVL mutation (6%), prothrombin G20210A mutation (13%), AT deficiency (20%), PC deficiency (30%), and PS deficiency (29%) in the whole cohort. This evidence concerns the gene F5 and pyruvate carboxylase deficiency disease.